ANEB
Anebulo Pharmaceuticals, Inc.
Set alert
0.26 USD -0.02 -5.45%
0.8699 Day range 0.8699
0.001 52-week range 2.64
- YTD
- -74.26%
- 1 year
- -90.15%
- Open
- 0.8699
- Prev close
- 0.275
- Mkt cap
- 10.60M
- Vol
- 100
- Avg vol
- 184
- EPS
- -0.19
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.8699
- High
- 0.8699
- Forward P/E
- -2.49
- Beta
- -1.01
- Short ratio
- 1.94
- Inst. own
- 28.32%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 11, 2025
- 50-d avg
- 1.60
- 200-d avg
- 2.14
- 1y target
- 8.00
Financial health
Altman Z-Score
-8.89 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
1 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C2 / 5 overall
- DCF 4
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 1
- P/E 1
- P/B 2
Valuation
P/E -5.8×
FY 2020 5y median -5.8× FY 2025
P/S 0.0×
FY 2020 5y median 0.0× FY 2025
P/B 4.2×
FY 2020 5y median 7.4× FY 2025
P/FCF -7.7×
FY 2020 5y median -8.6× FY 2025
EV/EBITDA -4.8×
FY 2020 5y median -4.8× FY 2025
EV/Sales 0.0×
FY 2020 5y median 0.0× FY 2025
FCF Yield -13.0%
FY 2020 5y median -11.7% FY 2025
Profitability
Gross Margin 0.0%
FY 2020 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2020 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2020 5y median 0.0% FY 2025
ROE -72.8%
FY 2020 5y median -110.7% FY 2025
ROIC -77.4%
FY 2020 5y median -77.4% FY 2025
ROA -69.9%
FY 2020 5y median -100.5% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2020 FY 2025
Operating Income -11.0%
FY 2020 FY 2025
EPS (diluted) 21.9%
FY 2020 FY 2025
Free Cash Flow 21.5%
FY 2020 FY 2025
Financial Health
Current Ratio 53.4×
FY 2020 5y median 30.4× FY 2025
Quick Ratio 53.4×
FY 2020 5y median 30.4× FY 2025
Debt / Equity 0.0×
FY 2020 5y median 0.0× FY 2025
Net Debt / EBITDA 1.5×
FY 2020 5y median 1.0× FY 2025
Interest Coverage -24.1×
FY 2020 5y median -24.1× FY 2025
Dividends
Dividend Yield 0.0%
FY 2020 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2020 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-06-30